头孢哌酮-舒巴坦治疗慢性阻塞性肺疾病急性加重期的效果分析.docVIP

精品论文 参考文献 头孢哌酮-舒巴坦治疗慢性阻塞性肺疾病急性加重期的效果分析 顾文欣 孙焕淇 汪洋 　　（辽宁省本溪市中心医院药学部 117000） 　　【摘要】目的：评价头孢哌酮-舒巴坦在治疗慢性阻塞性肺疾病急性加重期的疗效。方法 回顾性分析本院2011年1月到2013年1月收治的慢性阻塞性肺疾病急性加重期患者共100例随机分为观察组抗菌药物采用头孢哌酮-舒巴坦和对照组抗菌药物采用头孢他啶，连续治疗2周。结果 两组患者临床疗效比较，观察组总有效率为92%明显高于对照组总有效率78%，Plt;0.05差异有统计学意义。两组患者主要不良反应为恶心、呕吐、食欲不振、皮疹等，Pgt;0.05差异无统计学意义。结论 头孢哌酮-舒巴坦作为慢性阻塞性肺疾病急性加重期治疗的经验用药，临床疗效良好，不良反应轻微。 　　【关键词】头孢哌酮-舒巴坦 慢性阻塞性肺疾病 急性加重期 　　【中图分类号】R969 【文献标识码】A 【文章编号】1672-5085（2014）05-0043-01 　　 　　【Abstract】 Objective To evaluate the efficacy of cefoperazone - Shubatan in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Methods a retrospective analysis of 100 cases of patients were randomly divided into the observation group of antibiotics with cefoperazone - Shubatan and the control group with ceftazidime antibiotics in our hospital from 2011 January to 2013 January in our hospital, acute exacerbation of chronic obstructive pulmonary disease, all patients were treated for 2 weeks. Results compared the clinical efficacy of the two groups, the observation group the total effective rate was 92%, significantly higher than that in the control group the total efficiency of 78%, there are significant differences Plt;0.05. The main adverse reactions of the two groups patients were nausea and vomiting, loss of appetite, skin rash, comparison of major adverse reactions of the two groups, the difference had no statistical significance (Pgt;0.05). Conclusion Cefoperazone - Shubatan as acute exacerbation of chronic obstructive pulmonary disease treatment experience of drug use, good efficacy, mild adverse reactions. 　　【Key words】Cefoperazone - Shubatan chronic obstructive pulmonary disease acute exacerbation 　　慢性阻塞性肺疾病（COPD）是常见的呼吸系统疾病，严重危害患者的身心健康，引起COPD急性发病的最常见原因是呼吸道感染，以细菌感染最为多见[1]。笔者回顾分析本院收治的慢性阻塞性肺疾病急性加重期患者共100例临床资料，现报告如下。 　　1 资料与方法 　　1.1一般资料　随机选取我院2011年1月到2013年1月收治的慢性阻塞性肺疾病急性加重期患者100例。其中男性59例，女性41例。年龄43-71岁，平均年龄59plusmn;1.6岁。 随机分为观察组和对照组